As of November 7, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Cartesian Therapeutics Inc. The largest reported stake is Murat Kalayoglu's, at 19.9%. 8 filings are on record since November 5, 2025 (Schedule 13D/A, April 2, 2026).
Who owns Cartesian Therapeutics, Inc.?
Sell to companies like Cartesian Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Barclays PLC · Sole voting: 0 · Shared voting: 19,462 · Sole dispositive: 0 · Shared dispositive: 19,462 · SCHEDULE 13G/A, 2026-11-06
- · Holder: Barclays PLC · Percent: 5.99% · SCHEDULE 13G
- · Reporting person: Jpmorgan Chase & Co. · Sole voting: 1,397,213 · Shared voting: 0 · Sole dispositive: 1,486,252 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-22
- · Holder: Fmr LLC · Percent: 3% · SCHEDULE 13G/A
- · Holder: Murat Kalayoglu · Percent: 19.9% · SCHEDULE 13D/A
Cartesian Therapeutics Inc has 8 Schedule 13D or 13G filings on record since 2025-11-05. 2 holders' latest filing reports 5% or more of common-stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 19.9% | 5,833,971 | SCHEDULE 13D/A, 2026-04-02 | 2026-03-31 | |
| Squarepoint Ops LLC | 8.3% | 2,209,601 | SCHEDULE 13G, 2026-03-13 | 2026-03-09 |
| Jpmorgan Chase & Co. | 4.8% | 1,486,252 | SCHEDULE 13G/A, 2026-07-22 | 2026-06-30 |
| Fmr LLC | 3% | 799,743 | SCHEDULE 13G/A, 2026-05-06 | 2026-03-31 |
| Barclays PLC | 0.02% | 7,233 | SCHEDULE 13G/A, 2026-11-06 | 2026-09-30 |
Holding shares or following this stake? See who's behind Cartesian Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Cartesian Therapeutics Inc and the records around it.
Cartesian Therapeutics Inc elsewhere on the record
- Leadership changes May 2026
- Who owns it
Companies that share a holder
- Squarepoint Ops LLC also filed stake reports on 1 other company: LENZ Therapeutics, Inc. (Apr 2026)
- Barclays PLC also filed stake reports on 116 other companies: BIGLARI HOLDINGS INC-B (Nov 2026), CABLE ONE INC (Nov 2026), CALISA ACQUISITION CORP (Nov 2026)
- JPMORGAN CHASE & CO. also filed stake reports on 116 other companies: LEVI STRAUSS & CO (Nov 2026), Warner Music Group Corp. (Nov 2026), Andersen Group Inc. (Oct 2026)
Watch Cartesian Therapeutics Inc
Get an email when Cartesian Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cartesian Therapeutics Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cartesian Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cartesian Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Jpmorgan Chase & Co. | 1,397,213 | 0 | 1,486,252 | 0 | SCHEDULE 13G/A, 2026-07-22 |
| Barclays PLC | 0 | 19,462 | 0 | 19,462 | SCHEDULE 13G/A, 2026-11-06 |
The latest filing identifies Cartesian Therapeutics Inc by CUSIP 816212302 and gives its principal executive office as 7495 New Horizon Way, Frederick, MD 21703 (SCHEDULE 13G/A, 2026-11-06).
Purpose of Transaction (Item 4)
Murat Kalayoglu
Item 4 of the Schedule 13D is supplemented as follows: On March 31, 2026, Murat Kalayoglu resigned as a member of the Issuer's board of directors. On April 2, 2026, pursuant to a Notice of Optional Conversion delivered to the Issuer by the Trust pursuant to Section 6.02 of the Certificate of Designation, as amended by the Amendment to the Certificate of Designation, 22,740.030 shares of Series A Preferred Stock held by the Trust were converted into 758,001 shares of Common Stock.Item 4 of the SCHEDULE 13D/A filed 2026-04-02
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-05 | Fmr LLC | 8.3% | SCHEDULE 13G/A |
| 2026-02-05 | Fmr LLC | 5.3% | SCHEDULE 13G/A |
| 2026-03-13 | Squarepoint Ops LLC | 8.3% | SCHEDULE 13G |
| 2026-04-02 | Murat Kalayoglu | 19.9% | SCHEDULE 13D/A |
| 2026-05-06 | Fmr LLC | 3% | SCHEDULE 13G/A |
| 2026-07-22 | Jpmorgan Chase & Co. | 4.8% | SCHEDULE 13G/A |
| 2026-08-13 | Barclays PLC | 5.99% | SCHEDULE 13G |
| 2026-11-06 | Barclays PLC | 0.02% | SCHEDULE 13G/A |
Questions about who owns Cartesian Therapeutics Inc
Who owns Cartesian Therapeutics Inc?
On this page, 2 holders' latest ownership filings report 5% or more of Cartesian Therapeutics Inc: Murat Kalayoglu (19.9%, Schedule 13D/A, filed 2026-04-02) and Squarepoint Ops LLC (8.3%, Schedule 13G, filed 2026-03-13).
Who are the largest shareholders of Cartesian Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Cartesian Therapeutics Inc on this page are Murat Kalayoglu (19.9%) and Squarepoint Ops LLC (8.3%).
When did Murat Kalayoglu buy into Cartesian Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Murat Kalayoglu on this page is the Schedule 13D/A, filed 2026-04-02, reporting 19.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Cartesian Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 26, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| March 30, 2026 | Leadership change: Murat Kalayoglu departs, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Cartesian Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.